Showing results (131-140 of 6,853) with videos related to
Sort By:
Pageof 686
Journal of Medical Economics|July 12, 2011
Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk scoreSean D Sullivan, Louis P Garrison, Harald Rinde, et al.Frontiers in Pharmacology|April 25, 2022
Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy ImplicationsAndrás Incze, Zoltán Kaló, Jaime Espín, et al.Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 27, 2016
Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-upLouis P Garrison, Marita R Zimmermann, Christopher H Young, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 1, 2025
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare DiseasesWalter Toro, Min Yang, Anish Patel, et al.International Journal of Technology Assessment in Health Care|January 21, 2016
RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACHRuth Puig-Peiro, Anne Mason, Jorge Mestre-Ferrandiz, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2012
Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force reportMarc L Berger, Nancy Dreyer, Fred Anderson, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportLouis P Garrison, Peter J Neumann, Pennifer Erickson, et al.Vaccines|May 25, 2017
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United StatesBlythe J S Adamson, Josh J Carlson, James G Kublin, et al.Pharmacoeconomics|June 9, 2023
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key DriversAurelie Meunier, Louise Longworth, Manuel Gomes, et al.Journal of Managed Care & Specialty Pharmacy|August 3, 2015
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)William J Canestaro, Daryl E Pritchard, Louis P Garrison, et al.Pageof 686